Detail akcie CryoLife online

Business Summary: Artivion, Inc. is engaged in manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Artivion Inc revenues increased 14% to $441.3M. Net income applicable to common stockholders totaled $9.8M vs. loss of $13.3M. Revenues reflect Medical devices segment increase of 19% to $345.8M, International segment increase of 14% to $227.3M, United States segment increase of 13% to $214.1M. Net Income reflects Other (income) expense, net - Balancing increase from $15.3M (expense) to $18K (income).